Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth

被引:0
|
作者
M Aggarwal
R Saxena
E Sinclair
Y Fu
A Jacobs
M Dyba
X Wang
I Cruz
D Berry
B Kallakury
S C Mueller
S D Agostino
G Blandino
M L Avantaggiati
F-L Chung
机构
[1] Lombardi Comprehensive Cancer Center,Department of Oncology
[2] Georgetown University,Department of Biochemistry and Molecular and Cellular Biology
[3] Georgetown University,undefined
[4] National Institutes of Arthritis and Musculoskeletal and Skin Diseases,undefined
[5] National Institutes of Health,undefined
[6] Translational Oncogenomics Unit,undefined
[7] Italian National Cancer Institute 'Regina Elena',undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Mutations in the p53 tumor-suppressor gene are prevalent in human cancers. The majority of p53 mutations are missense, which can be classified into contact mutations (that directly disrupts the DNA-binding activity of p53) and structural mutations (that disrupts the conformation of p53). Both of the mutations can disable the normal wild-type (WT) p53 activities. Nevertheless, it has been amply documented that small molecules can rescue activity from mutant p53 by restoring WT tumor-suppressive functions. These compounds hold promise for cancer therapy and have now entered clinical trials. In this study, we show that cruciferous-vegetable-derived phenethyl isothiocyanate (PEITC) can reactivate p53 mutant under in vitro and in vivo conditions, revealing a new mechanism of action for a dietary-related compound. PEITC exhibits growth-inhibitory activity in cells expressing p53 mutants with preferential activity toward p53R175, one of the most frequent ‘hotspot’ mutations within the p53 sequence. Mechanistic studies revealed that PEITC induces apoptosis in a p53R175 mutant-dependent manner by restoring p53 WT conformation and transactivation functions. Accordingly, in PEITC-treated cells the reactivated p53R175 mutant induces apoptosis by activating canonical WT p53 targets, inducing a delay in S and G2/M phase, and by phosphorylating ATM/CHK2. Interestingly, the growth-inhibitory effects of PEITC depend on the redox state of the cell. Further, PEITC treatments render the p53R175 mutant sensitive to degradation by the proteasome and autophagy in a concentration-dependent manner. PEITC-induced reactivation of p53R175 and its subsequent sensitivity to the degradation pathways likely contribute to its anticancer activities. We further show that dietary supplementation of PEITC is able to reactivate WT activity in vivo as well, inhibiting tumor growth in xenograft mouse model. These findings provide the first example of mutant p53 reactivation by a dietary compound and have important implications for cancer prevention and therapy.
引用
收藏
页码:1615 / 1627
页数:12
相关论文
共 50 条
  • [21] Mutant p53 depletion: a possible mechanism of inhibition of human prostate cancer by dietary phenethyl iscithiocyanate
    Mi, Lixin
    Wang, Thomas T. Y.
    Huang, Haiqiu
    Fletcher, Arnetta
    Yu, Lu
    Wang, Xiantao
    Chung, Fung-Lung
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [22] Zinc metallochaperones for mutant p53 reactivation in cancer therapeutics
    Yu, Xin
    Na, Bing
    Zaman, Saif
    Withers, Tracy
    Gilleran, John
    Blayney, Alan J.
    Bencivenga, Anthony F.
    Blanden, Adam R.
    Liu, Yue
    Boothman, David A.
    Loh, Stewart N.
    Kimball, S. David
    Ganesan, Shridar
    Carpizo, Darren R.
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [23] Reactivation of mutant p53: molecular mechanisms and therapeutic potential
    Selivanova, G.
    Wiman, K. G.
    [J]. ONCOGENE, 2007, 26 (15) : 2243 - 2254
  • [24] Reactivation of mutant p53: molecular mechanisms and therapeutic potential
    G Selivanova
    K G Wiman
    [J]. Oncogene, 2007, 26 : 2243 - 2254
  • [25] Therapeutic reactivation of mutant p53 protein by quinazoline derivatives
    Sutherland, Hamish S.
    Hwang, In Young
    Marshall, Elaine S.
    Lindsay, Brent S.
    Denny, William A.
    Gilchrist, Catherine
    Joseph, Wayne R.
    Greenhalgh, Debra
    Richardson, Emma
    Kestell, Philip
    Ding, Angela
    Baguley, Bruce C.
    [J]. INVESTIGATIONAL NEW DRUGS, 2012, 30 (05) : 2035 - 2045
  • [26] A role for bioinorganic chemistry in the reactivation of mutant p53 in cancer
    Jessica J. Miller
    Kalvin Kwan
    Christian Gaiddon
    Tim Storr
    [J]. JBIC Journal of Biological Inorganic Chemistry, 2022, 27 : 393 - 403
  • [27] Mutant p53 reactivation as a novel strategy for cancer therapy
    Wiman, KG
    Stridh, H
    Zache, N
    Rökaeus, N
    Issaeva, N
    Hammarsund, M
    Shen, JF
    Bergman, J
    Westman, J
    Selivanova, G
    Bykov, VJN
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 23 - 24
  • [28] Reactivation of mutant p53 by capsaicin, the major constituent of peppers
    Garufi, Alessia
    Pistritto, Giuseppa
    Cirone, Mara
    D'Orazi, Gabriella
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35
  • [29] Reactivation of mutant p53: a new strategy for cancer therapy
    Selivanova, G
    Kawasaki, T
    Ryabchenko, L
    Wiman, KG
    [J]. SEMINARS IN CANCER BIOLOGY, 1998, 8 (05) : 369 - 378
  • [30] Therapeutic reactivation of mutant p53 protein by quinazoline derivatives
    Hamish S. Sutherland
    In Young Hwang
    Elaine S. Marshall
    Brent S. Lindsay
    William A. Denny
    Catherine Gilchrist
    Wayne R. Joseph
    Debra Greenhalgh
    Emma Richardson
    Philip Kestell
    Angela Ding
    Bruce C. Baguley
    [J]. Investigational New Drugs, 2012, 30 : 2035 - 2045